Document Detail


Developmental outcome in very low birthweight infants. Current status and future trends.
MedLine Citation:
PMID:  9653444     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Surfactant therapy has significantly reduced mortality, but not morbidity, in the very low birthweight (VLBW) infant. Questions persist as to the edge of viability, the allocation of health care resources for the VLBW infant, and whether or not we are improving survival at the cost of contributing more handicapped individuals to society. Since surfactant alone has not reduced morbidity, other medical and behavioral treatments are being studied that may help to optimize neurodevelopmental outcome in the VLBW infant.
Authors:
J Bregman
Related Documents :
16021414 - Sibling birthweight as a predictor of macrosomia in women with type 1 diabetes.
15832544 - Neurobehavioural profile of low-birthweight infants with cystic periventricular leukoma...
12108064 - Two key strategies in the nutritional management of the extremely low birth weight infant.
15512064 - Perinatal factors influencing survival in extremely low-birthweight infants.
25023324 - A transdisciplinary approach to the decision-making process in extreme prematurity.
3509974 - Neonatal morphometrics and perinatal outcome: who is growth retarded?
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pediatric clinics of North America     Volume:  45     ISSN:  0031-3955     ISO Abbreviation:  Pediatr. Clin. North Am.     Publication Date:  1998 Jun 
Date Detail:
Created Date:  1998-07-16     Completed Date:  1998-07-16     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0401126     Medline TA:  Pediatr Clin North Am     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  673-90     Citation Subset:  AIM; IM    
Affiliation:
Department of Pediatrics, Evanston Northwestern Healthcare, Evanston Hospital, Illinois, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Child
Cost-Benefit Analysis
Developmental Disabilities / etiology*,  prevention & control
Humans
Infant, Newborn
Infant, Very Low Birth Weight*
Morbidity
Pulmonary Surfactants / economics,  therapeutic use*
Respiratory Distress Syndrome, Newborn / complications,  drug therapy*,  mortality
Survival Analysis
Treatment Outcome
Chemical
Reg. No./Substance:
0/Pulmonary Surfactants

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Principles of disease management in neonatology.
Next Document:  The death of a baby in the infant special care unit.